Merck and Isomorphic Labs have announced a new research collaboration aimed at developing oncology drug candidates. The partnership, revealed on Thursday, will leverage Isomorphic Labs' proprietary drug design engine alongside Merck's existing wet lab data to target an undisclosed oncology target of "strategic importance." Merck will oversee the preclinical and clinical development, manufacturing, and commercialization of any resulting products.
George Addona, global head of discovery, preclinical development, and translational medicine at Merck, highlighted the strategic significance of the target. He noted that Merck has already invested internal efforts into this area and believes that combining their datasets with Isomorphic's drug discovery technology could yield powerful results.
This collaboration marks another instance of a major pharmaceutical company partnering with Isomorphic Labs, known for its artificial intelligence-driven drug design capabilities. The technology is built on Nobel-winning advancements that can model how molecules bind to proteins, potentially accelerating the drug discovery process.